<DOC>
	<DOCNO>NCT01940484</DOCNO>
	<brief_summary>This observational study evaluate efficacy use Methoxy polyethylene glycol-epoetin beta ( Mircera ) participant Stage V chronic kidney disease hemodialysis receive erythropoietin prior study entry . Attending physician make decision place participant methoxy polyethylene glycol epoetin beta advance relate study . The therapy administer attendant treating physician accord specification package insert guideline routine site .</brief_summary>
	<brief_title>An Observational Study Methoxy Polyethylene Glycol-Epoetin Beta ( Mircera ) Stage V Chronic Kidney Disease Participants Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Participants chronic renal anemia Stage V chronic kidney disease hemodialysis hemoglobin level 10.0 13.0 gram per deciliter ( g/dL ) Participants receive ESA prior enter study Female participant childbearing age use effective contraceptive method As per approved package insert Any contraindication ESA treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>